<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04985604</url>
  </required_header>
  <id_info>
    <org_study_id>DAY101-102</org_study_id>
    <nct_id>NCT04985604</nct_id>
  </id_info>
  <brief_title>DAY101 Monotherapy or in Combination With Other Therapies for Patients With Solid Tumors</brief_title>
  <official_title>A Phase 1b/2, Open Label Study of DAY101 Monotherapy or Combination With Other Therapies for Patients With Recurrent, Progressive, or Refractory Solid Tumors Harboring MAPK Pathway Aberrations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Day One Biopharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>DOT Therapeutics-1 Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b/2, multi-center, open label umbrella study of patients ≥12 years of age&#xD;
      with recurrent or progressive solid tumors with alterations in the key proteins of the&#xD;
      RAS/RAF/MEK/ERK pathway.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study DAY101-102 (master study) and sub-studies will consist of a screening period, a&#xD;
      treatment period, a safety follow-up period, and a long-term follow-up period where survival,&#xD;
      status and subsequent anticancer therapies are collected.&#xD;
&#xD;
      Substudy DAY101-102a is a Phase 2, multi-center, open-label sub-study of patients ≥12 years&#xD;
      of age with recurrent or progressive solid tumors with activating BRAF fusion or CRAF1/RAF1&#xD;
      fusions or amplification. Patients with these alterations will be identified through&#xD;
      molecular assays as routinely performed at Clinical Laboratory Improvement Amendments of 1988&#xD;
      (CLIA) or other similarly certified laboratories. In this sub-study, patients will be&#xD;
      enrolled either into a melanoma cohort or an &quot;tissue agnostic&quot; cohort.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 15, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2025</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluate the efficacy of DAY101</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>Overall response rate (ORR) as assessed by proportion of patients with best overall confirmed response of complete response (CR) or partial response (PR) by RECIST version 1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess the safety and tolerability of DAY101</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>Type, incidence, and severity of treatment-emergent adverse events and laboratory abnormalities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess additional efficacy parameters of DAY101</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>Duration of response (DOR) in patients with best overall response of CR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assess additional efficacy parameters of DAY101</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>Duration of progression-free survival (PFS)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize tumor responses observed with DAY101</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>Time to response (TTR) in patients with best overall response of CR or PR; and comparing the DOR in patients with CR or PR with the DOR observed with the immediate prior line of anticancer treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the pharmacokinetic (PK) profile of DAY101</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>Measure plasma concentration of DAY101</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize the pharmacodynamic (PD) profile of DAY101</measure>
    <time_frame>Up to 48 months</time_frame>
    <description>Evaluate changes from baseline of phosphorylated ERK and other relevant biomarkers</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">43</enrollment>
  <condition>Melanoma</condition>
  <condition>Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Arm #1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>DAY101 monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DAY101</intervention_name>
    <description>DAY101 tablet for oral use. Other names: TAK580, MLN2480</description>
    <arm_group_label>Arm #1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed informed consent by patients ≥18 years of age and, assent for patients ≥ 12 up&#xD;
             to &lt; 18 years of age&#xD;
&#xD;
          -  Patients must have a histologically confirmed diagnosis of non-hematologic tumor with&#xD;
             an activating BRAF fusion, CRAF/RAF1 fusion, or CRAF/RAF1 amplification.&#xD;
&#xD;
          -  Patients must have radiographically-recurrent or radiographically-progressive disease&#xD;
             that is measurable using the appropriate tumor response criteria (e.g. RECIST version&#xD;
             1.1)&#xD;
&#xD;
          -  Archival tumor tissue (preferably less than 3 years old) or fresh tumor tissue for&#xD;
             correlative studies is required&#xD;
&#xD;
          -  If brain metastases are present, they must have been previously treated and be stable&#xD;
             as assessed by radiographic imaging&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior therapy with BRAF-, MEK-, or MAPK-directed inhibitor therapy, except for tumor&#xD;
             types and indications where such therapy has been approved by the FDA or applicable&#xD;
             regulatory authorities&#xD;
&#xD;
          -  Known presence of concurrent activating mutation&#xD;
&#xD;
          -  Patients with current evidence or a history of central serous retinopathy (CSR),&#xD;
             retinal vein occlusion (RVO)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Day One Biopharmaceuticals</last_name>
    <phone>650-484-0899</phone>
    <email>clinical@dayonebio.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>The Angeles Clinic</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saba Mukarram</last_name>
      <phone>310-231-2181</phone>
      <email>smukarram@theangelesclinic.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hoag Health</name>
      <address>
        <city>Newport Beach</city>
        <state>California</state>
        <zip>92663</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Price</last_name>
      <phone>949-764-4510</phone>
      <email>wendy.price@hoag.org</email>
    </contact>
    <contact_backup>
      <last_name>Clinical Research Main Line</last_name>
      <phone>949-764-5543</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Colorado Hospital</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Intake CRC</last_name>
      <email>POEMSintake@cuanschutz.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cancer Specialists of North Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mary Alice Anderson</last_name>
      <email>maryalice.anderson@csnf.us</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami Sylvester Comprehensive Cancer Center</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Janet McIntosh</last_name>
      <email>jxa1221@med.miami.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>OHSU Knight Cancer Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Knight Clinical Trials Information Line</last_name>
      <phone>503-494-1080</phone>
      <email>Phase1@ohsu.edu; trials@ohsu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 23, 2021</study_first_submitted>
  <study_first_submitted_qc>July 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2021</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Melanoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

